2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. CA VI Isoform

CA VI

Carbonic anhydrase VI (CA VI) is a zinc-dependent enzyme that catalyzes the reversible hydration of carbon dioxide and is the only secreted isoform within the human α-carbonic anhydrase family[1][2]. CA VI is produced primarily by serous acinar cells of the salivary and mammary glands and is secreted into saliva and milk, where it contributes to extracellular acid-base regulation and surface homeostasis[1][3]. Mechanistically, CA VI participates in pH regulation by accelerating the conversion of carbon dioxide and bicarbonate, thereby supporting buffering processes on oral and upper alimentary tract surfaces[1][4]. This activity is closely linked to maintenance of the enamel pellicle and protection against excessive acid exposure in the oral cavity and gastrointestinal mucosa[1][5]. Disease-associated studies have reported that reduced salivary CA VI levels are associated with increased prevalence of dental caries and acid-related epithelial disorders, supporting its relevance as a biomarker and functional component of mucosal defense[1][5]. Compared with other carbonic anhydrase isoforms, CA VI is distinguished by its extracellular secretion and unique C-terminal structural features, whereas most related α-carbonic anhydrases function as intracellular, membrane-associated, or mitochondrial enzymes[2]. Structural characterization further demonstrated that human CA VI forms oligomeric assemblies and remains susceptible to inhibition by the classical carbonic anhydrase inhibitor acetazolamide, making it a useful experimental model for investigating extracellular carbonic anhydrase biology and inhibitor interactions[2][6].

CA VI Related Products (2):

Cat. No. Product Name Effect Purity
  • HY-109056
    Elsulfavirine
    		Inhibitor 99.90%
    Elsulfavirine (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer.
  • HY-109056A
    Elsulfavirine sodium
    		Inhibitor
    Elsulfavirine sodium (R-1206) is an orally active human carbonic anhydrase (carbonic anhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonic anhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer.